The creator of CRISPR babies is flirting again with infamy, this time through a mysterious alliance with an Internet-savvy ...

STAT reporters chat about the mood in the gene editing field, M&A deals in biotech, and leadership changes at Novo Nordisk.

Beam Therapeutics CEO John Evans warns against AI hype in drug development, drawing parallels to past CRISPR expectations, ...

A “genetic surgery” or “interventional genetics” system for individualized treatments would be a marriage of drug development ...

Gene editing, once a theoretical ambition, has matured into a revolutionary frontier in biotechnology. Technologies like CRISPR-Cas9, TALENs, and Zinc Finger Nucleases (ZFNs) have unlocked ...

Most of the 15 million children with a rare disease have no FDA-approved treatments available to them. And when it comes to ...

Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).

For centuries, yeast has been an essential ingredient in the production of wine and bread. Scientists are able to adjust ...

BURLINGAME, CA, UNITED STATES, May 20, 2025 /EINPresswire.com/ -- Biotechnology Market is estimated to be valued at USD 1,034.63 Bn in 2025 and is expected to reach USD 2,330.47 Bn in 2032, exhibiting ...

U.S. technology is set to “do very well” under the administration of President Trump, and one sector in particular, said Ark ...

Researchers at the University of Colorado Boulder and Oak Ridge National Laboratory have developed a new way to identify ...

The infant was born with a metabolic disorder called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, in which the ...